Sonoma Pharmaceuticals, Inc. announced the appointment of Philippe Weigerstorfer to the company’s board of directors. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma’s board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. Weigerstorfer will replace Russ Harrison who is retiring from Sonoma’s board of directors after four and a half years of service.